China NMPA Drug Inspection - Shishou City Diaoguan Central Health Center - Andrographis paniculata

The Hubei Provincial Food and Drug Administration released an announcement on August 28, 2015 (published November 28, 2019), detailing the outcomes of drug quality supervision and sampling inspections conducted across Hubei Province, China, during the second quarter of 2015. These inspections involved various drug production, distribution, and utilization units. A comprehensive list of 178 non-compliant drug items was identified, indicating a failure to meet established quality standards. Violations primarily included deficiencies in drug properties, identification (e.g., microscopic characteristics, thin-layer chromatography), and examination for specific impurities such as sulfur dioxide residue, auramine 0, or rosin. Issues related to content determination, moisture levels, ash content, and dosage uniformity were also common. Notably, the report also flagged several instances of counterfeit drugs and products that were not genuinely produced by the stated manufacturers.

The regulatory framework underpinning these inspections encompassed the Chinese Pharmacopoeia (2010 Edition), various supplementary inspection methods approved by the State Food and Drug Administration, and specific national and provincial drug standards. In response to these findings, regulatory departments are mandated to investigate and penalize non-compliant entities in accordance with drug supervision laws. Required actions include intensified follow-up sampling, tracing the supply chains of counterfeit drugs, and referring cases involving suspected criminal activity to public security authorities for legal action, all aimed at enhancing public drug safety.